The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Promising first real-world CIBMTR data for liso-cel in R/R mantle cell lymphoma
Elise Chong, MD, Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, discusses the first real-world CIBMTR dataset evaluating lisocabtagene maraleucel (liso-cel), a CD19-directed CAR T-cell therapy, in relapsed/refractory (R/R) mantle cell lymphoma. Dr Chong highlights high response rates and encouraging durability, with outcomes consistent with those reported in the pivotal TRANSCEND-NHL-001 MCL cohort (NCT02631044). This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is the first real-world data because liso-cel for mantle cell lymphoma was only approved in the U.S. in May of 2024, and so this is literally the earliest data we have. The response rates were excellent, and all of it was consistent with what was shown in the TRANSCEND mantle cell lymphoma cohort. The overall response rate was 89%. CR rate was 79%. We had six months of follow-up, and of those six months of follow-up, the six-month median, at six months, the duration of response was 81%, the progression-free survival was 79%, and the overall survival was 92%...
This is the first real-world data because liso-cel for mantle cell lymphoma was only approved in the U.S. in May of 2024, and so this is literally the earliest data we have. The response rates were excellent, and all of it was consistent with what was shown in the TRANSCEND mantle cell lymphoma cohort. The overall response rate was 89%. CR rate was 79%. We had six months of follow-up, and of those six months of follow-up, the six-month median, at six months, the duration of response was 81%, the progression-free survival was 79%, and the overall survival was 92%.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
